Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

Related Articles

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

5 months ago

Is Hims & Hers' $1.15 Billion Eucalyptus Acquisition a Game-Changer for Global Telehealth

5 months ago

Is the FDA Poised to Reshape the Peptide Market

3 months ago

What's Driving Veracyte's Impressive Stock Rally

2 months ago

Category

You may also like

Stock News•3 days ago

QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says 'Peptides Are Fake Medicine'

Martin Shkreli disclosed a short position in Hims & Hers Health (HIMS), calling its peptide products 'fake medicine.' The move adds a high-profile bearish voice to the stock.

HIMS

Share

Stock News•3 days ago

Hims & Hers stands to gain if the FDA loosens restrictions on peptides

Hims & Hers Health could access a multi-billion-dollar peptide market if the FDA loosens manufacturing restrictions, per analysts.

HIMS

Share

Stock News•3 weeks ago

HIMS Breakout Signals Structural Business Transformation

HIMS stock surged from below $14 to above $37 after a regulatory shock, driven by over 100,000 monthly weight-loss subscriber additions and a diversified growth narrative.

HIMS

Share

Stock News•2 months ago

Hims & Hers: I See No New Red Flags

Hims & Hers shares fell ~14% in pre-market trading following a Q1 report that missed investor expectations. Despite the decline, management maintains an upbeat Q2 outlook, citing specific timing issue...

HIMS

Share